Xenon Pharmaceuticals Inc (XENE) Looking At a $2 Billion Opportunity Here [Yahoo! Finance]
Xenon Pharmaceuticals Inc. - Common Shares (XENE)
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.xenon-pharma.com
Company Research
Source: Yahoo! Finance
data from the Phase 3 X-TOLE2 study of its epilepsy drug candidate, azetukalner, at the American Academy of Neurology Annual Meeting in Chicago. Xenon Pharmaceuticals Inc (XENE) Looking At a $2 Billion Opportunity Here Xenon used the event to highlight the study's strong results. It also used the platform to talk about its plans to seek regulatory approval for azetukalner. In the late-stage study, patients treated with azetukalner showed a 53.2% reduction in monthly seizure frequency at the 25 mg dose. At the 15 ?mg dose, the monthly seizure frequency reduced by 34.5%. Those in the placebo group showed a 10.4% reduction. Some patients achieved complete seizure control. Xenon revealed that the rate of 100% seizure reduction increased over time as patients remained in the therapy. In the final four weeks of the trial, 13.7% of patients in the 25 mg group and 12.8% of those in the 15 mg group achieved complete seizure control. That compared to 4.0% for the placebo group. The st
Show less
Read more
Impact Snapshot
Event Time:
XENE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XENE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XENE alerts
High impacting Xenon Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
XENE
News
- Xenon's Phase 3 Supports A 'Buy' Despite Its Premium [Seeking Alpha]Seeking Alpha
- Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual MeetingGlobeNewswire
- Xenon to Present at Upcoming Investor ConferencesGlobeNewswire
- Xenon Pharmaceuticals (XENE) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
XENE
Earnings
- 2/26/26 - Miss
XENE
Sec Filings
- 4/22/26 - Form ARS
- 4/22/26 - Form DEFA14A
- 4/22/26 - Form DEF
- XENE's page on the SEC website